AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30914909 — intervention group
Group type: COMPARATOR
Intervention: Insertion of needles on the non-acupuncture points without stimulation
Number of subjects: 24
Study 30914970 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel nutraceutical compound containing red yeast rice, polymethoxyflavones, and antioxidants, dosage and duration not available
Number of subjects: 0
Study 30915015 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep Bruxism
Number of subjects: 0
Study 30915015 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 30915029 — intervention group
Group type: EXPERIMENTAL
Intervention: Acipimox administration with exercise
Number of subjects: 0
Study 30915112 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative TG levels in benign group (median 167.5 ng/mL)
Number of subjects: 50
Study 30915112 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative TG levels measured at 7-14 days, 4 weeks, 6 weeks, and 3 months
Number of subjects: 50
Study 30915112 — intervention group
Group type: EXPERIMENTAL
Intervention: Preexisting hypothyroidism and hyperthyroidism in malignant group
Number of subjects: 50
Study 30915112 — intervention group
Group type: EXPERIMENTAL
Intervention: TG elimination half-life
Number of subjects: 50
Study 30915112 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative TG levels
Number of subjects: 50
Study 30915273 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib plus Erlotinib
Number of subjects: 0
Study 30915620 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-support intervention to link veterans to health-related services after incarceration
Number of subjects: 16000
Study 30915626 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphate-free formulation of etanercept (50 mg)
Number of subjects: 111
Study 30915626 — intervention group
Group type: COMPARATOR
Intervention: Prior formulation of etanercept (50 mg)
Number of subjects: 111
Study 30915685 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftaroline
Number of subjects: 166
Study 30915685 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 166
Study 30915922 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab (TECENTRIQ®) plus chemotherapy (Abraxane; nab®-Paclitaxel)
Number of subjects: 0
Study 30915992 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose i.v. naloxone infusion (total dose 3.25 mg kg)
Number of subjects: 8
Study 30915996 — intervention group
Group type: EXPERIMENTAL
Intervention: VCPD
Number of subjects: 345
Study 30915996 — intervention group
Group type: EXPERIMENTAL
Intervention: ANI
Number of subjects: 345
Study 30915996 — intervention group
Group type: EXPERIMENTAL
Intervention: PD
Number of subjects: 345
Study 30915996 — intervention group
Group type: EXPERIMENTAL
Intervention: PLR
Number of subjects: 345
Study 30916032 — intervention group
Group type: EXPERIMENTAL
Intervention: Photoplethysmographic signal monitoring during anaesthesia induction
Number of subjects: 0
Study 30916032 — intervention group
Group type: EXPERIMENTAL
Intervention: Photoplethysmographic signal parameters
Number of subjects: 0
Study 30916608 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 30916659 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentric pedaling-type interval exercise (CON)
Number of subjects: 30
Study 30916659 — intervention group
Group type: COMPARATOR
Intervention: Eccentric pedaling-type interval exercise (ECC)
Number of subjects: 30
Study 30916661 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumaini smartphone game intervention
Number of subjects: 60
Study 30916661 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 60
Study 30916665 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone with built-in accelerometer, gyroscope, and phone orientation sensor; used for 3 consecutive days at home.
Number of subjects: 150
Study 30916665 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone with built-in accelerometer, gyroscope, and phone orientation sensor; used during clinic appointment.
Number of subjects: 150
Study 30916665 — intervention group
Group type: COMPARATOR
Intervention: Control group (subjects without PD); measured using the same smartphone device.
Number of subjects: 150
Study 30916768 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal Cord Stimulation (SCS)
Number of subjects: 17
Study 30917688 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency catheter ablation
Number of subjects: 142
Study 30917689 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous implantable cardioverter-defibrillator shock at 65 J
Number of subjects: 282
Study 30917689 — intervention group
Group type: COMPARATOR
Intervention: Suboptimal device position
Number of subjects: 282
Study 30917689 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower body mass index
Number of subjects: 282
Study 30917689 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower shock impedance
Number of subjects: 282
Study 30917689 — intervention group
Group type: EXPERIMENTAL
Intervention: White race
Number of subjects: 282
Study 30917689 — intervention group
Group type: EXPERIMENTAL
Intervention: Appropriate system position
Number of subjects: 282
Study 30917793 — intervention group
Group type: EXPERIMENTAL
Intervention: Microgrants ($2000) and financial incentives ($500) for increasing group PA
Number of subjects: 87
Study 30917871 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose interleukin-2 (HD IL-2)
Number of subjects: 810
Study 30917871 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose interleukin-2 (HD IL-2) alone
Number of subjects: 810
Study 30918029 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (1000 mg)
Number of subjects: 0
Study 30918039 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI-EFW at 36 + 0 to 36 + 6 weeks of gestation
Number of subjects: 2004
Study 30918039 — intervention group
Group type: COMPARATOR
Intervention: 2D US-EFW
Number of subjects: 2004
Study 30918100 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimethyl fumarate (DMF) treatment
Number of subjects: 0
Study 30918100 — intervention group
Group type: EXPERIMENTAL
Intervention: DMF treatment
Number of subjects: 0
Study 30918874 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal-bolus regimen in DM1 patients
Number of subjects: 0
Study 30918874 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal-bolus regimen in DM2 patients
Number of subjects: 0
Study 30918874 — intervention group
Group type: COMPARATOR
Intervention: Comparison of insulin doses normalized for body weight
Number of subjects: 0
Study 30918874 — intervention group
Group type: COMPARATOR
Intervention: Relationship of b/T ratio with glycemic control and hypoglycemia
Number of subjects: 0
Study 30918950 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab plus cobimetinib
Number of subjects: 150
Study 30919658 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 19
Study 30919658 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 30919658 — intervention group
Group type: COMPARATOR
Intervention: Nonmedicated ADHD
Number of subjects: 19
Study 30920187 — intervention group
Group type: EXPERIMENTAL
Intervention: Current opioid agonist treatment (buprenorphine maintenance)
Number of subjects: 375
Study 30920187 — intervention group
Group type: EXPERIMENTAL
Intervention: Current mutual-help group attendance
Number of subjects: 375
Study 30920187 — intervention group
Group type: EXPERIMENTAL
Intervention: Current outpatient counseling
Number of subjects: 375
Study 30920244 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Activation System (BAS) measures
Number of subjects: 0
Study 30920244 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Inhibition System (BIS) measures
Number of subjects: 0
Study 30920244 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain intensity
Number of subjects: 0
Study 30920244 — intervention group
Group type: EXPERIMENTAL
Intervention: Frontal alpha asymmetry (FAA)
Number of subjects: 0
Study 30920851 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 17000
Study 30920851 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17000
Study 30921081 — intervention group
Group type: EXPERIMENTAL
Intervention: Apical suspension
Number of subjects: 236
Study 30921081 — intervention group
Group type: COMPARATOR
Intervention: No apical suspension
Number of subjects: 236
Study 30921255 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with PMS who are continent
Number of subjects: 17
Study 30921255 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with PMS who are incontinent
Number of subjects: 17
Study 30921255 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with PMS receiving gastrointestinal specialty care
Number of subjects: 17
Study 30922100 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant treatment
Number of subjects: 664
Study 30922152 — intervention group
Group type: EXPERIMENTAL
Intervention: Group progressive resistance training
Number of subjects: 54
Study 30922152 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill training
Number of subjects: 54
Study 30922152 — intervention group
Group type: COMPARATOR
Intervention: Both interventions
Number of subjects: 54
Study 30922241 — intervention group
Group type: EXPERIMENTAL
Intervention: Jehovah's Witnesses patients after cardiac surgery
Number of subjects: 31
Study 30922248 — intervention group
Group type: EXPERIMENTAL
Intervention: Icaritin 600 or 800 mg b.i.d.
Number of subjects: 20
Study 30922265 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon tamponade (Group A)
Number of subjects: 125
Study 30922265 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon tamponade and bilateral uterine artery ligation (Group B)
Number of subjects: 125
Study 30922265 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral uterine artery ligation and cervix as natural tamponade (Group C)
Number of subjects: 125
Study 30922276 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylnaltrexone
Number of subjects: 327
Study 30922276 — intervention group
Group type: EXPERIMENTAL
Intervention: Enemas, methylnaltrexone, or 4-l polyethylene-glycol solution
Number of subjects: 327
Study 30922276 — intervention group
Group type: COMPARATOR
Intervention: Oxycodone
Number of subjects: 327
Study 30922276 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 327
Study 30922276 — intervention group
Group type: COMPARATOR
Intervention: Morphine equivalent daily dose
Number of subjects: 327
Study 30922283 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-level intervention on IPV reduction
Number of subjects: 620
Study 30922315 — intervention group
Group type: EXPERIMENTAL
Intervention: T1DM patients with poor glycemic control
Number of subjects: 26
Study 30922315 — intervention group
Group type: EXPERIMENTAL
Intervention: T1DM patients with optimal glucose control
Number of subjects: 26
Study 30922315 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 26
Study 30922315 — intervention group
Group type: EXPERIMENTAL
Intervention: T1DM patients (varied glycemic control)
Number of subjects: 26
Study 30922356 — intervention group
Group type: EXPERIMENTAL
Intervention: Music listening sessions (1-hour sessions provided by volunteer musicians)
Number of subjects: 152
Study 30922356 — intervention group
Group type: COMPARATOR
Intervention: Non-exposed group (no music listening sessions)
Number of subjects: 152
Study 30922468 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid PET/MRI
Number of subjects: 100
Study 30922643 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic endometritis (CE) diagnosed by CD138 IHC staining
Number of subjects: 167
Study 30922643 — intervention group
Group type: COMPARATOR
Intervention: No chronic endometritis (NCE)
Number of subjects: 167
Study 30922805 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of pertuzumab, subcutaneous trastuzumab, and taxane chemotherapy
Number of subjects: 50
Study 30922862 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoballoon focal ablation system (CbFAS) performed using side-by-side applications of 10 seconds, repeated at 3-month intervals until complete response (CR) was established.
Number of subjects: 80
Study 30922870 — intervention group
Group type: EXPERIMENTAL
Intervention: Orsiro sirolimus-eluting coronary stent with biodegradable polymer
Number of subjects: 1356
Study 30922934 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic Hypothermia (32.0-34.0 °C)
Number of subjects: 204
Study 30922934 — intervention group
Group type: COMPARATOR
Intervention: Normothermia (36.0-37.5 °C)
Number of subjects: 204
Study 30922934 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (THAPCA-OH and THAPCA-IH)
Number of subjects: 204
Study 30922934 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month VABS-II and PCPC outcomes
Number of subjects: 204
Study 30923464 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium (200 μg/day) and Coenzyme Q10 (200 mg/day)
Number of subjects: 219
Study 30923464 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 219
Study 30923749 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component quality improvement (QI) strategy
Number of subjects: 1146
Study 30923820 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-PD-1 therapy (pembrolizumab or nivolumab)
Number of subjects: 185
Study 30924406 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumococcal conjugate vaccines (PCVs) - ≥1 dose ≥ age 2 months
Number of subjects: 610
Study 30924406 — intervention group
Group type: EXPERIMENTAL
Intervention: Early onset otitis media (OM)
Number of subjects: 610
Study 30924406 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent OM episodes (≥8 episodes)
Number of subjects: 610
Study 30924406 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 610
Study 30924548 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregivers of patients with GA impairments
Number of subjects: 414
Study 30924548 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregivers of patients with higher numbers of GA domain impairments
Number of subjects: 414
Study 30924548 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregivers of patients with impaired function
Number of subjects: 414
Study 30924548 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregivers of patients with impaired nutrition
Number of subjects: 414
Study 30924579 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin degludec
Number of subjects: 1887
Study 30924579 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine U100
Number of subjects: 1887
Study 30924606 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted sacrocolpopexy (RASC)
Number of subjects: 305
Study 30924606 — intervention group
Group type: EXPERIMENTAL
Intervention: Supracervical hysterectomy with sacrocervicopexy (RSHS)
Number of subjects: 305
Study 30924737 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanreotide
Number of subjects: 44
Study 30924737 — intervention group
Group type: COMPARATOR
Intervention: Octreotide LAR
Number of subjects: 44
Study 30924789 — intervention group
Group type: EXPERIMENTAL
Intervention: ExPRESS mobile phone app for monitoring early signs, basic symptoms, and psychotic symptoms used for 6 months.
Number of subjects: 18
Study 30924924 — intervention group
Group type: EXPERIMENTAL
Intervention: BRV (100 mg, intravenous)
Number of subjects: 13
Study 30924924 — intervention group
Group type: EXPERIMENTAL
Intervention: BRV (200 mg, intravenous)
Number of subjects: 13
Study 30924924 — intervention group
Group type: COMPARATOR
Intervention: LEV (1500 mg, intravenous)
Number of subjects: 13
Study 30924924 — intervention group
Group type: EXPERIMENTAL
Intervention: BRV (50-100 mg, oral, twice-daily for 4 days)
Number of subjects: 13
Study 30924924 — intervention group
Group type: COMPARATOR
Intervention: LEV (250-600 mg, oral, 4 hours postdose)
Number of subjects: 13
Study 30924938 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion of 6'6'H2 glucose
Number of subjects: 57
Study 30925139 — intervention group
Group type: EXPERIMENTAL
Intervention: High parent-reported stress
Number of subjects: 689
Study 30925139 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate parent-reported stress
Number of subjects: 689
Study 30925139 — intervention group
Group type: COMPARATOR
Intervention: Low parent-reported stress
Number of subjects: 689
Study 30925890 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulator-based practice sessions with practice coordinators
Number of subjects: 125
Study 30925890 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulator-based practice sessions
Number of subjects: 125
Study 30925890 — intervention group
Group type: EXPERIMENTAL
Intervention: Ongoing support and scheduling of practice sessions
Number of subjects: 125
Study 30926067 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI measurements
Number of subjects: 150
Study 30926081 — intervention group
Group type: EXPERIMENTAL
Intervention: Decitabine 30 mg plus cedazuridine 100 mg
Number of subjects: 44
Study 30926081 — intervention group
Group type: EXPERIMENTAL
Intervention: Decitabine 40 mg plus cedazuridine 100 mg
Number of subjects: 44
Study 30926081 — intervention group
Group type: COMPARATOR
Intervention: Intravenous decitabine
Number of subjects: 44
Study 30926081 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall adverse events
Number of subjects: 44
Study 30926081 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events leading to death
Number of subjects: 44
Study 30926081 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive disease and respiratory failure
Number of subjects: 44
Study 30926187 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography
Number of subjects: 1216
Study 30926187 — intervention group
Group type: COMPARATOR
Intervention: Clinical evaluation
Number of subjects: 1216
Study 30926572 — intervention group
Group type: EXPERIMENTAL
Intervention: Salivary microRNA panel (4 microRNAs)
Number of subjects: 443
Study 30926572 — intervention group
Group type: EXPERIMENTAL
Intervention: Salivary microRNAs
Number of subjects: 443
Study 30927064 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-dairy diets (Q4, 274-1429 g/day dairy)
Number of subjects: 1655
Study 30927096 — intervention group
Group type: EXPERIMENTAL
Intervention: Women (726 patients)
Number of subjects: 2087
Study 30927096 — intervention group
Group type: COMPARATOR
Intervention: Men (1361 patients)
Number of subjects: 2087
Study 30927096 — intervention group
Group type: EXPERIMENTAL
Intervention: Propensity score-matched cohort (506 patients)
Number of subjects: 2087
Study 30927531 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS plus DCB (PRO-Kinetic Energy BMS stent followed by Pantera Lux DCB)
Number of subjects: 432
Study 30927531 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS plus DCB
Number of subjects: 432
Study 30928173 — intervention group
Group type: EXPERIMENTAL
Intervention: FSME-IMMUN vaccination after 3-dose primary immunization
Number of subjects: 358
Study 30928173 — intervention group
Group type: EXPERIMENTAL
Intervention: First booster of FSME-IMMUN
Number of subjects: 358
Study 30928173 — intervention group
Group type: EXPERIMENTAL
Intervention: Second booster of FSME-IMMUN
Number of subjects: 358
Study 30928393 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of age, BMI, PlGF, and MMP9 for OSA identification
Number of subjects: 361
Study 30928393 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI alone
Number of subjects: 361
Study 30928393 — intervention group
Group type: EXPERIMENTAL
Intervention: Age alone
Number of subjects: 361
Study 30928393 — intervention group
Group type: EXPERIMENTAL
Intervention: PlGF alone
Number of subjects: 361
Study 30928393 — intervention group
Group type: EXPERIMENTAL
Intervention: MMP9 alone
Number of subjects: 361
Study 30928393 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical measures and biomarkers combined
Number of subjects: 361
Study 30928907 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline measurements of heart rate variability (HRV) and median nerve conduction velocity (NCV) prior to long-term occupational lead exposure
Number of subjects: 328
Study 30928934 — intervention group
Group type: EXPERIMENTAL
Intervention: High fibre intake
Number of subjects: 57053
Study 30928934 — intervention group
Group type: EXPERIMENTAL
Intervention: Red meat intake
Number of subjects: 57053
Study 30928934 — intervention group
Group type: EXPERIMENTAL
Intervention: Processed meat intake
Number of subjects: 57053
Study 30928955 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral positioning
Number of subjects: 74
Study 30928955 — intervention group
Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 74
Study 30929153 — intervention group
Group type: EXPERIMENTAL
Intervention: PA-adjusted WOMAC pain scores (adjusted for step count)
Number of subjects: 122
Study 30929153 — intervention group
Group type: EXPERIMENTAL
Intervention: PA-adjusted WOMAC pain scores (adjusted for energy expenditure)
Number of subjects: 122
Study 30929153 — intervention group
Group type: COMPARATOR
Intervention: Unadjusted WOMAC pain score
Number of subjects: 122
Study 30929188 — intervention group
Group type: EXPERIMENTAL
Intervention: Blephapad Combo treatment arm (wet wipes with terpinen-4-ol and hyaluronic acid)
Number of subjects: 18
Study 30929188 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment arm (wet and warm gauze)
Number of subjects: 18
Study 30929188 — intervention group
Group type: EXPERIMENTAL
Intervention: Blephapad Combo treatment arm
Number of subjects: 18
Study 30929188 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment arm
Number of subjects: 18
Study 30929188 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment arms
Number of subjects: 18
Study 30929225 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical exercise therapy for 3 months
Number of subjects: 16
Study 30929225 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical exercise therapy
Number of subjects: 16
Study 30929556 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon Dilation (BD)
Number of subjects: 75
Study 30929556 — intervention group
Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 75
Study 30929556 — intervention group
Group type: COMPARATOR
Intervention: Stent
Number of subjects: 75
Study 30929571 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic retinal vessel analysis (DVA) measuring maximum venular dilation (vMax) in response to flicker light stimulation.
Number of subjects: 214